Novartis receives EU approval for Cosentyx label update

ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.

The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday.

(Reporting by Silke Koltrowitz)

Related News

Executive who drove Uber's international expansion leaves

Nov 30, 2017

US-UBER-EUROPE:Executive who drove Uber's international expansion leaves

Philadelphia sues Wells Fargo, alleges predatory lending

May 15, 2017

US-WELLSFARGO-PHILADELPHIA:Philadelphia sues Wells Fargo, alleges predatory lending

Traders drain pricey U.S. oil storage as OPEC deal bites

Feb 24, 2017

US-USA-OIL-STORAGE-ANALYSIS:Traders drain pricey U.S. oil storage as OPEC deal bites

Must Read

Executive who drove Uber's international expansion leaves

Nov 30, 2017

US-UBER-EUROPE:Executive who drove Uber's international expansion leaves

Philadelphia sues Wells Fargo, alleges predatory lending

May 15, 2017

US-WELLSFARGO-PHILADELPHIA:Philadelphia sues Wells Fargo, alleges predatory lending

Traders drain pricey U.S. oil storage as OPEC deal bites

Feb 24, 2017

US-USA-OIL-STORAGE-ANALYSIS:Traders drain pricey U.S. oil storage as OPEC deal bites

Search
You May Need To Know

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales@obserworld.com